P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients

Authors :: Yu Deng
S. Lam
Filippo de Marinis
Roy S. Herbst
Simonetta Mocci
Alan Sandler
Giuseppe Giacconne
Jacek Jassem
Ariel Lopez-Chavez
David R. Spigel
Source :: Journal of Thoracic Oncology. 12:S1299-S1300
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Chemotherapy
biology
business.industry
medicine.medical_treatment
Atezolizumab
Internal medicine
PD-L1
medicine
biology.protein
business
Chemotherapy naive

Full Text Access

Tools